Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.F02 in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis
NCT06047171Phase 2Recruiting
- Sponsor
- Alentis Therapeutics
- Start
- Sep 2023
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of lixudebart in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and rapidly progressive glomerulonephritis (RPGN) (4 arms), sponsored by Alentis Therapeutics. Primary endpoint: Safety and tolerability of ALE.F02 at 1 year. Started Sep 2023; status: recruiting.
02
Drugs
lixudebart
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)rapidly progressive glomerulonephritis (RPGN)
Beyond the preview
Go deeper on NCT06047171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047171.